Arthur Beaudet

Early life and education Beaudet was born in Woonsocket, Rhode Island. His medical dissertation at Yale was titled, "Differences in RNA codon recognition as a function of cellular tRNA content".

Beaudet completed a residency in pediatrics at Johns Hopkins Hospital in 1969 and a postdoctoral fellowship at the National Institutes of Health two years later. After his NIH fellowship ended in 1971, Beaudet began his affiliation with Baylor. He retired from Baylor in January 2020.

Research Beaudet began his research in the 1960s with studies on protein synthesis. In the 1970s, Beaudet et al. demonstrated mutations in cultured somatic cells; he has also conducted much research on inborn errors of metabolism, particularly urea cycle disorders. In 1988, Beaudet's laboratory published a paper regarding the mechanism by which uniparental disomy might cause certain types of human genetic disease. This paper proposed four mechanisms for uniparental disomy, each of which has since been shown to occur. and that deletion of the snoRNAs likely contributes to the Prader-Willi phenotype. In collaboration with Isis (now Ionis) Pharmaceuticals he demonstrated that oligonucleotides could be used to activate the paternal allele of Ube3a in the mouse as a possible therapeutic correction in Angelman syndrome.

Beaudet has published research on the possible association between the deficiency of a carnitine biosynthesis gene and risk of autism in boys, and has contended that some of these cases of autism may be preventable through carnitine supplementation. Beaudet has also developed a test which enables doctors to detect whether or not a child was conceived as a result of incest without testing either parent. Beaudet has worked for over a decade trying to develop a commercial form of cell-based noninvasive prenatal testing using fetal cells in the mother’s blood during the first trimester.

Beaudet has been a principal investigator at the Howard Hughes Medical Institute.